CPluxprev2020: Postural Management for Hip Luxation in Quadriplegic Cerebral Palsy

Sponsor
Azienda Unità Sanitaria Locale Reggio Emilia (Other)
Overall Status
Recruiting
CT.gov ID
NCT04603625
Collaborator
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (Other), Ospedale IRCCS G. Gaslini di Genova (Other), IRCCS Eugenio Medea (Other), IRCCS Don Carlo Gnocchi di Firenze (Other), Azienda Unita' Sanitaria Locale Di Modena (Other), Azienda Usl di Bologna (Other), Azienda Unità Sanitaria Locale della Romagna (Other), Azienda ULSS di Verona e Provincia (Other), Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (Other)
102
1
2
29.9
3.4

Study Details

Study Description

Brief Summary

Cerebral palsy (CP) is the most common motor disability in childhood. Among these, hip luxation represents the most frequent and clinically relevant one, affecting 72% of non-ambulatory CP children. Reconstructive surgical treatment is debated in severe CP children, for whom it is crucial to identify an effective preventive approach. The aim of our study is to verify if keeping a sitting position centering femoral heads is more effective than usual postural management (sitting with the trunk aligned and hips abducted), in preventing hip luxation in quadriplegic CP children. It's a multicenter randomized controlled study (13 sites involved). A total of 102 quadriplegic CP children, aged 1-6 years-old, classified as Gross Motor Function Measure System 4 or 5, will be recruited and randomized to usual or experimental sitting, at least 5 hours a day, for 2 years. The primary outcome will be the degree of luxation, measured by means of the Migration Percentage (MP), on pelvic radiography, at 12 and 24 months. Secondary outcomes will include compliance and Health Related-Quality of Life, using validated tools, hip pain, device cost, MRI lesions, concurrent direct neuromotor treatment, use of standing devices and spasticity treatments (botulinum toxin, per os or intrathecal baclofen, selective dorsal rhizotomy). Experimental sitting is expected to reduce the MP change compared to usual care. It will be of interest to compare compliance, QoL and costs in either groups: aspects affecting the effectiveness. Furthermore to evaluate correlations between MP and spasticity treatments, MRI lesion type, and other clinical features.

Condition or Disease Intervention/Treatment Phase
  • Other: postural management
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
102 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Physicians measuring Migration Percentage (Primary Outcome) will be blind
Primary Purpose:
Prevention
Official Title:
Postural Management to Prevent Hip Luxation in Quadriplegic Cerebral Palsy Children: Comparing Two Approaches in a Randomized Controlled Trial
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: sitting position centering femoral heads

sitting position centering femoral heads according to Lespargot diagram

Other: postural management
postural management in sitting position

Active Comparator: Usual postural management

sitting with the trunk aligned and hips abducted to facilitate activities of daily living

Other: postural management
postural management in sitting position

Outcome Measures

Primary Outcome Measures

  1. Change in Migration Percentage [Day 0, Month 12, Months 24]

    measure of hip luxation on pelvic radiography

Secondary Outcome Measures

  1. Caregiver Priorities & Child Health Index of Life with Disabilities (CPCHILD) [Day 0, Month 12, Month 24]

    Parents will fill in a questionnaire about Health Related Quality of Life referred to their child. Minimum value 0, maximum value 100, higher scores mean a better outcome.

  2. Quebec User Evaluation of Satisfaction with Assistive Technology (IT-QUEST) [Month 12, Month 24]

    Parents will fill in a questionnaire measuring their satisfaction about the assistive device ensuring the desired sitting position of their child. Minimum value 1, maximum value 5,higher scores mean a better outcome.

  3. Incidence of pain [Day 0, Month 6, Month 12, Month 18, Month 24]

    Care givers will be interviewed about presence or absence of hip pain in the previous months during personal care and activities of daily living

  4. Assistive devices costs [Day 0, Month 6, Month 12, Month 18, Month 24]

    Costs paid by Health Institution for sitting systems used during the study

  5. Percentage of patients attending Botulinum Toxin-A injections [Day 0, Month 6, Month 12, Month 18, Month 24]

    Botulinum Toxin-A injections in muscles around the hip during the study will be recorded

  6. Percentage of patients attending direct physical treatment [Day 0, Month 6, Month 12, Month 18, Month 24]

    Physiotherapy, other Neuromotor Therapy during the study

  7. Percentage of patients using standing devices in abduction [Day 0, Month 6, Month 12, Month 18, Month 24]

    It will be recorded if the patients will be using standing devices at least 5 hours/week, less than 5 h/week or never

  8. Type of CP (Dyskinetic or spastic) [Day 0]

    Type of CP will be recorded to evaluate any association with MP change

  9. Percentage of patients having Intrathecal Baclofen (ITB) [Day 0]

    It will be recorded if patients have ITB to evaluate any association with MP change

  10. Percentage of patients taking Baclofen per os [Day 0, Month 6, Month 12, Month 18, Month 24]

    Baclofen oral medication during the study will be recorded

  11. Percentage of patients who underwent Selective Dorsal Rhizotomy (SDR) [Day 0]

    It will be recorded if patients underwent SDR in the past to evaluate any association with MP change

  12. Age [Day 0]

    Age will be recorded to evaluate any association with MP change

  13. Sex [Day 0]

    Sex will be recorded to evaluate any association with MP change

  14. Type of lesion at MRI [Day 0]

    Type of lesion at MRI, according to Neonatal Neuroimaging Classification System (maldevelopments | predominant white matter injury | predominant grey matter injury | miscellaneous | Normal). Data will be registered based on previously acquired MRI, considering that the exam is mandatory for the diagnosis of cerebral palsy. It will be recorded to evaluate any association with MP change

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Year to 6 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Cerebral palsy spastic or dyskinetic

  • GMFCS 4 or 5

  • MP<41%

  • Informed Consent acquired

Exclusion Criteria:
  • muscle contracture overcoming defined passive Range Of Motion (ROM)limits

  • anterior hip luxation

  • previous reconstructive hip surgery

  • preventive surgery in previous 12 months

  • lumbar scoliosis >20° Cobb

Contacts and Locations

Locations

Site City State Country Postal Code
1 Azienda Unità Sanitaria Locale Reggio Emilia Reggio Emilia Italy

Sponsors and Collaborators

  • Azienda Unità Sanitaria Locale Reggio Emilia
  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
  • Ospedale IRCCS G. Gaslini di Genova
  • IRCCS Eugenio Medea
  • IRCCS Don Carlo Gnocchi di Firenze
  • Azienda Unita' Sanitaria Locale Di Modena
  • Azienda Usl di Bologna
  • Azienda Unità Sanitaria Locale della Romagna
  • Azienda ULSS di Verona e Provincia
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Investigators

  • Study Chair: SILVIA FACCIOLI, Azienda Unità Sanitaria Locale Reggio Emilia

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Azienda Unità Sanitaria Locale Reggio Emilia
ClinicalTrials.gov Identifier:
NCT04603625
Other Study ID Numbers:
  • 723/2020/SPER/AUSLRE
First Posted:
Oct 27, 2020
Last Update Posted:
Oct 27, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Azienda Unità Sanitaria Locale Reggio Emilia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2020